###begin article-title 0
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
Large genomic rearrangements in the CFTR gene contribute to CBAVD
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 79 136 79 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR (Cystic Fibrosis Transmembrane Conductance Regulator</italic>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
By performing extensive scanning of whole coding and flanking sequences of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, we had previously identified point mutations in 167 out of 182 (91.7%) males with isolated congenital bilateral absence of the vas deferens (CBAVD). Conventional PCR-based methods of mutation analysis do not detect gross DNA lesions. In this study, we looked for large rearrangements within the whole CFTR locus in the 32 CBAVD patients with only one or no mutation.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We developed a semi-quantitative fluorescent PCR assay (SQF-PCR), which relies on the comparison of the fluorescent profiles of multiplex PCR fragments obtained from different DNA samples. We confirmed the gross alterations by junction fragment amplification and identified their breakpoints by direct sequencing.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 118 127 118 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTRdele2</italic>
###xml 205 219 205 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTRdele 22_24</italic>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
We detected two large genomic heterozygous deletions, one encompassing exon 2 (c.54-5811_c.164+2186del8108ins182) [or CFTRdele2], the other removing exons 22 to 24 (c.3964-3890_c.4443+3143del9454ins5) [or CFTRdele 22_24], in two males carrying a typical CBAVD mutation on the other parental CFTR allele. We present the first bioinformatic tool for exon phasing of the CFTR gene, which can help to rename the exons and the nomenclature of small mutations according to international recommendations and to predict the consequence of large rearrangements on the open reading frame.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
Identification of large rearrangements further expands the CFTR mutational spectrum in CBAVD and should now be systematically investigated. We have designed a simple test to specifically detect the presence or absence of the two rearrangements identified in this study.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 332 336 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 362 363 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 364 365 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 433 438 425 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 563 564 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 698 703 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 941 946 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 967 972 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1065 1066 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1067 1068 1051 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1121 1126 1105 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1189 1193 1173 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 1298 1299 1282 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1300 1301 1284 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1302 1303 1286 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1383 1388 1367 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1475 1480 1459 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1511 1512 1495 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1513 1514 1497 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1561 1566 1545 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1719 1727 <span type="species:ncbi:9606">patients</span>
Congenital bilateral absence of the vas deferens (CBAVD) accounts for approximately 3% of cases of male infertility in Caucasian populations. In about 85% of cases, CBAVD is recognized as an autosomal recessive disorder (MIMnot equal277180) associated with mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR, also symbolized ABCC7) [1-3]. Almost all of 1,500 different mutations so far identified in the CFTR gene in cystic fibrosis (CF) (MIMnot equal219700) or in related disorders (updates in the Cystic Fibrosis Mutation Database [4]) are single-nucleotide changes or small base pair(s) insertions or deletions in the exons or their flanking intronic sequences. The CFTR gene encodes a protein expressed in the apical membrane of exocrine epithelial cells which functions principally as a cAMP induced chloride channel and regulates also other ion channels. A combination of severe genetic changes in the two CFTR alleles that reduces CFTR function below 5% of physiological levels usually leads to the severe forms of classical CF [5,6]. Other so-called mild mutations that retain higher CFTR residual function can cause milder or incomplete phenotypes or CFTR-associated phenotypes. CBAVD is caused either by two mild mutations or by a severe and a mild mutation [3,7,8]. Routine testing for the most prevalent mutations in classical CF misses most CFTR gene alterations in the CBAVD phenotype, which can be detected only by scanning the 27 CFTR coding and flanking sequences [8,9]. However, despite exhaustive analysis of the CFTR gene, a proportion of mutations still remains unidentified in CBAVD, ranging from 15 to 40% depending both on the technologies used and the ethnicity of patients.
###end p 11
###begin p 12
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Recent studies in cases with classical cystic fibrosis suggested that gross rearrangements encompassing a single or several exons could account for a significant part of unidentified alleles. Large deletions have been discovered either fortuitously on the basis of uniparental inheritance of polymorphic markers [10-14] and Southern blotting [15] or through a systematic screening [16-19]. These mutations, when present at the heterozygous state, elude the PCR-based techniques designed to detect small DNA alterations.
###end p 12
###begin p 13
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
In CBAVD, there is paucity of information about large genomic rearrangements and only two have been reported so far but without information on breakpoints sequences [17,20].
###end p 13
###begin p 14
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
In this study, we used a semi-quantitative fluorescent multiplex PCR assay to screen samples from CBAVD patients that remained unresolved after extensive scanning of CFTR exons. Two large deletions have been identified, which further confirms the involvement of gross DNA alterations in CBAVD.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Nomenclature of mutations
###end title 16
###begin p 17
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 73 78 <span type="species:ncbi:9606">Human</span>
We followed the international nomenclature guidelines recommended in the Human Genome Variation Society web page [21]. However, for convenience to readers used to the nomenclature of the Cystic Fibrosis Mutation Database [4], the usual names of mutations are also indicated [in italic and in brackets].
###end p 17
###begin title 18
Recruitment of CBAVD Samples with One or No CFTR mutation
###end title 18
###begin p 19
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 310 350 310 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Denaturing Gradient Gel Electrophoresis</italic>
###xml 362 415 362 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">denaturing High Pressure Liquide phase Chromatography</italic>
###xml 681 694 681 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1811+1.6KbA&gt;G</italic>
###xml 716 728 716 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3849+10kbC&gt;T</italic>
###xml 961 966 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 993 994 993 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1297 1302 1297 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1331 1336 1331 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
###xml 1378 1386 <span type="species:ncbi:9606">patients</span>
Our current procedure to detect CFTR point mutations responsible for CBAVD includes the following steps: 1) the screening for 33 common CF mutations by using a commercial kit (CF OLA assay, Abbot, Rungis-France), 2) the scanning of all 27 exons and their intronic boundaries by using optimized laboratory DGGE (Denaturing Gradient Gel Electrophoresis) or dHPLC (denaturing High Pressure Liquide phase Chromatography) protocols, 3) the sequencing of any abnormal region to confirm and characterize the sequence change by using ABI Prism BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems). In addition, we also screen DNAs for intronic splicing mutations c.1679+1634A>G [1811+1.6KbA>G] and c.3717+10kbC>T [3849+10kbC>T] using PRC-restriction with appropriate enzymes. The whole procedure has been previously applied to each of the 182 unrelated patients with documented CBAVD who have been referred to our lab so far, allowing us to detect one or two CFTR mutations in 167 of them [[8] and unpublished results]. Here we have further studied the 32 samples remaining with one (n = 17) or no (n = 15) mutation. Whenever possible, we studied the familial segregation of mutations and variations in order to determine whether sequence changes were located on a single or on the two parental CFTR alleles. Informed consent to CFTR studies had been previously obtained from patients and relatives at the time of referral.
###end p 19
###begin title 20
Search of Gross Rearrangements in the CFTR Gene by SQF-PCR Analysis
###end title 20
###begin p 21
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1530 1532 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1574 1578 1537 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMD </italic>
We used a semi-quantitative fluorescent multiplex PCR assay (SQF-PCR) developed in our laboratory for the detection of exon deletions and duplications in the CFTR gene. The method relies on the comparison of the fluorescent profiles of multiplex PCR fragments obtained from different samples, the amplification being stopped at the exponential phase. The 27 exons were grouped into three multiplex PCRs with one primer of each pair 5'-labeled with the 6-FAM fluorochrome (oligonucleotide primers available upon request). Amplification mixture included 5 to 20 pmol of each primer and 150 ng of genomic DNA in a 20 mul volume. Concentration and quality of DNAs were thoroughly determined prior amplification reactions. The PCR cycling conditions were selected using QIAGEN Multiplex PCR Kit according to the manufacturer's instructions (Qiagen, Courtaboeuf, France). Amplifications were performed with an initial denaturation step at 95degreesC for 15 min, followed by 20 cycles of 30 s at 95degreesC denaturation, 90 s at 57degreesC annealing and 1 min extension at 72degreesC, followed by a final extension at 72degreesC for 10 min, using a Gene Amp 9700 Thermal Cycler (Applied Biosystems, Foster City, CA). Amplified DNA fragments were separated on an ABI 310 or 3130xl sequencer at 60degreesC. Using Genescan and Genotyper (ABI 310) or GeneMapper (ABI 3130xl) softwares, the data were analyzed by superimposing fluorescent profiles of test and control DNAs and by calculating dosage quotient for area and height of all peaks [22] after normalization with an exon of the DMD gene.
###end p 21
###begin title 22
Confirmation of Deletions by Junction Fragment Amplification
###end title 22
###begin p 23
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 378 389 378 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(this study</italic>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
We developed a simple and rapid test to confirm the identified deletions using two distinct duplex PCRs. For mutation c.54-5811_c.164+2186del8108ins182 [CFTRdele2], one pair of primers [23] amplifies wild type exon 2 while the other one has been designed to detect specifically the deleted allele [primers IVS1F (5'-TACACAAGGCTTGTCTTTAG-3') and IVS2R (5'GTTAAGCCAGATAATTCTGC-3' (this study)]. For mutation c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24], we used one pair of primers to amplify wild type exon 22 [23] and primers IVS21-3940F and TAG+3303R [15] to detect the junction fragment of the deletion. PCR products were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. This test ensures an internal amplification control and can distinguish between homozygous and heterozygous samples for the deletion.
###end p 23
###begin title 24
Identification of Breakpoints
###end title 24
###begin p 25
We characterized the two large rearrangements by sequencing the amplified fragments of genomic DNA encompassing the breakpoints using primers noted above.
###end p 25
###begin title 26
Computer-Assisted Sequence Analysis
###end title 26
###begin p 27
###xml 165 178 165 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RepeatMasker </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLAST </italic>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 487 491 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 531 533 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 534 536 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 781 786 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 328 333 <span type="species:ncbi:9606">Human</span>
Large portions of genomic DNA sequences within and around the rearrangements were searched for both low complexity/simple repeats and interspersed repeats using the RepeatMasker program and were analyzed for sequence similarity using the BLAST tool available through UCSC (University of California Santa Cruz) Genome Browser on Human (March 2006 assembly) [24]. To predict the effect of large deletions on the CFTR open reading frame sequences, we used the "exon-phasing tool" of the UMD(R) software (Universal Mutation Database) [25,26], which gives access to a graphical presentation of all coding exons of a gene according to their phasing in order to predict, at least at the genomic level, the consequence of the deletion of one or more exons on the open reading frame of the CFTR gene.
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Using a comprehensive CFTR gene analysis protocol we had previously identified CFTR mutations in 167/182 (91.7%) patients with documented CBAVD including 150 (82.4%) with two mutations and 17 (9.3%) with one mutation. In the current study we present the result of our investigations concerning the involvement of large rearrangements in the 32 remaining samples with one or no CFTR small mutation.
###end p 29
###begin title 30
Detection of two Complex CFTR Large Deletions and Confirmation of Deletion Breakpoint Junctions
###end title 30
###begin p 31
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 209 216 <span type="species:ncbi:9606">patient</span>
###xml 432 435 <span type="species:ncbi:9606">man</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
Using SQF-PCR, a large genomic deletion was identified in 2 (6.25%) of the 32 samples analyzed in this study. Rearrangement c.54-5811_c.164+2186del8108ins182 [CFTRdele2] (Figure 1A) was found in a 27-year-old patient originating from Southern Italia carrying on the other allele the typical CBAVD splice variant IVS8(TG)12T(5). Rearrangement c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Figure 1B) was found in a 41-year-old man with Spanish and Sicily background carrying the missense mutation p.Arg170His. Both large deletions were found to be associated with a 7T allele at the IVS8(Tn) locus. The presence of either of the two deletions was confirmed by specific duplex PCRs amplifying both wild-type and deleted alleles in heterozygote samples. DNA sequencing showed that deletions breakpoint junctions appeared to be the same as those recently described in two patients with cystic fibrosis as IVS1-5811_IVS2+2186del8108ins182 [27] or IVS21-3890_Stop+3143del9454ins5 [15].
###end p 31
###begin p 32
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [<italic>CFTR</italic>dele2] in CBAVD</bold>
###xml 141 152 141 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 819 824 819 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1058 1069 1058 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1179 1183 1179 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1352 1357 1352 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1432 1446 1432 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTRdele22_24 </italic>
###xml 1449 1453 1449 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 1360 1472 1360 1472 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B) Confirmation of complex deletion c.3964-3890_c.4443+3143del9454ins5 [<italic>CFTRdele22_24 </italic>or <italic>CFTR</italic>dele25_27] in CBAVD</bold>
###xml 1524 1535 1524 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 1620 1628 1620 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">22 to 24</italic>
###xml 2049 2054 2049 2054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 2198 2209 2198 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 2319 2323 2319 2323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 2492 2497 2492 2497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 961 968 <span type="species:ncbi:9606">patient</span>
###xml 1861 1868 <span type="species:ncbi:9606">patient</span>
A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [CFTRdele2] in CBAVD. Rearrangement c.54-5811_c.164+2186del8108ins182 (upper panel) consists of a gross deletion of 8108 bp spanning exon 2 (dotted area) and an insertion of 182 bp (grey area) at the deletion junction between the nucleotide 54-5811 of intron 1 (IVS1 nt 18294) and the nucleotide 164+2186 of intron 2 (IVS2 nt 2186) [according to the recommended international nomenclature with the A of the ATG start codon numbered as +1]. The 182-bp insertion is part of intron 3 between IVS3 nucleotides 6780 and 6961 but in inverted orientation (arrow). This complex in/del is also termed c.186-5811_c.296+2186del8108+ins182 with the A of the ATG translation start codon numbered as +133 in accordance with the GenBank reference sequence for the CFTR gene on chromosome 7 (NM_000492.2) and the CF mutation database [4]. It was recently reported as IVS1-5811_IVS2+2186del8108ins182 in one patient with cystic fibrosis [27]. A specifically-designed junction fragment amplification test (lower panel) confirmed the presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels (left) by comparison with the non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted sequences were determined by direct sequencing (right). B) Confirmation of complex deletion c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24 or CFTRdele25_27] in CBAVD. Rearrangement c.3964-3890_c.4443+3143del9454ins5 (upper panel) consists of a gross deletion of 9454 bp (dotted area) encompassing exons 25 to 27 [22 to 24], the stop codon and the poly(A) signal. A small insertion of 5 bases (TAACT) was observed at the junction but is too small to allow any determination of its origin (arrow). The same rearrangement has recently been described in one patient with cystic fibrosis as c.4096-3890_c.4575+3143del9454ins5 with the A of the ATG translation start codon numbered as +133 in accordance with the GenBank reference sequence for the CFTR gene on chromosome 7 (NM_000492.2) or as IVS21-3890Stop+3143del9454insTAACT [15]. A specifically-designed junction fragment amplification test (lower panel) confirmed the presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels (left) by comparison with the non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted sequences were determined by direct sequencing (right).
###end p 32
###begin title 33
Analysis of Genomic Sequences and Exon Phasing of the CFTR Gene
###end title 33
###begin p 34
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Despite the presence of Interspersed repeat elements in the vicinity of the rearrangements (Figure 1), there is no significant homology flanking the deletion breakpoints or insertion junctions to suggest that homologous recombination has occurred.
###end p 34
###begin p 35
###xml 34 38 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 48 50 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 75 80 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 242 246 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 284 289 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 434 438 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 457 458 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The "exon-phasing tool" of the UMD(R) software [25] uses a numerotation of CFTR exons in accordance with international nomenclatures and predicts an in-frame deletion of exon 2 (36 amino acids) for mutation c.54-5811_c.164+2186del8108ins182 [CFTRdele2] and the loss of the three last CFTR coding sequences (exons 22 to 24, that should be numbered 25 to 25, totalizing 159 amino acids) for mutation c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Figure 2).
###end p 35
###begin p 36
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Exon phasing of the <italic>CFTR </italic>gene (Universal Mutation Database [25])</bold>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 343 378 343 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">University of California Santa Cruz</italic>
###xml 638 655 638 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left end of exons</italic>
###xml 856 874 856 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right end of exons</italic>
###xml 380 385 <span type="species:ncbi:9606">Human</span>
Exon phasing of the CFTR gene (Universal Mutation Database [25]). The CFTR gene comprises 27 exons which were previously numbered 1-24 [23] with subdivisions A and B for exons 6, 14 and 17, recognized as distinct units after the initial publication of the gene (GenBank ). Here we presents the numerotation of CFTR exons as described in UCSC (University of California Santa Cruz) Human Genome databases and updated as March 2006 Assembly [24]. Each exon is presented as a blue box with the international numbering within the box, and the familiar numbering above it. Each extremity of the box represents the specific phasing of the exon. Left end of exons: 1) vertical extremity: the exon begins by the first nucleotide of a codon; 2) curve: the exon begins by the second nucleotide of a codon; 3) arrow: the exon begins by the third nuceotide of a codon. Right end of exons: 1) vertical extremity: the exon ends by the last nucleotide of a codon; 2) light blue curve: the exon ends by the first nucleotide of a codon; 3) arrow: the exon ends by the second nucleotide of a codon. Large-scale deletions can introduce a translational frameshift (and lead to a premature termination codon) when two exons are joined end to end (for example, exons 1 and 4). When two exons in the same phase are joined, it is assumed that no frameshift occurs and that a shorter protein with an internal deletion may be produced.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1019 1024 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1492 1497 1492 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1611 1616 1611 1616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1662 1664 1662 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1772 1774 1772 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1775 1777 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
Despite the accumulated information about genomic rearrangements in patients with cystic fibrosis, where they account for up to 16 to 24% of CF alleles negative for point mutations in European populations [15-18][27], only two large exonic rearrangements have been described so far in CBAVD [17,20]. The SQF-PCR protocol described in the present study enables the rapid and reliable detection of unknown CFTR gene deletions or duplications in CF or CBAVD. We identified two large rearrangements in two males carrying a typical CBAVD mutation on the other parental CFTR allele in a sample of 32 patients, which elucidates 4.25% of alleles that remained unidentified after standard investigations for point mutations. The remaining unsolved alleles might be explained by mutations in CFTR non-coding regions not explored by genomic DNA-based available methods or by the contribution of other(s) gene(s) to CBAVD. However if we postulate that, for most of the 15 patients with no mutation, CBAVD is probably not linked to CFTR defects, large rearrangements could represent 12% (2/17 alleles) of unidentified alleles, which is in the range of figures observed in the CF population. With this hypothesis, searching for large rearrangements in addition to conventional genotyping would identify two mutations in 152/167 (91%) and one mutation in 15/167 (9%) of CBAVD males. The two deletions found in our CBAVD samples are predicted to be "severe" alleles precluding the production of a functional CFTR protein and are thus null mutations. Bioinformatic analysis of the sequences flanking large rearrangements in the CFTR gene suggest that non-homologous end joining [28] is the most likely mechanism that is responsible for their occurrence, in accordance with recent studies [17,27].
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
Screening for large genomic rearrangements in the CFTR gene is beneficial not only in classical cystic fibrosis but also in CBAVD, especially for those males who are carriers of a CFTR mild mutation. This study strengthens the importance to include screening of gross rearrangements in CFTR mutations scanning to offer adequate diagnosis and genetic counselling for CBAVD couples. International numerotation of exons should be used in order to avoid future misdiagnosis.
###end p 40
###begin title 41
Abbreviations
###end title 41
###begin p 42
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
CFTR, cystic fibrosis transmembrane conductance regulator
###end p 42
###begin p 43
CBAVD, congenital bilateral absence of the vas deferens
###end p 43
###begin p 44
CF, cystic fibrosis
###end p 44
###begin p 45
bp, base pair
###end p 45
###begin p 46
PCR, polymerase chain reaction
###end p 46
###begin p 47
SQF-PCR, semi-quantitative fluorescent PCR assay
###end p 47
###begin title 48
Competing interests
###end title 48
###begin p 49
The author(s) declare that they have no competing interests.
###end p 49
###begin title 50
Authors' contributions
###end title 50
###begin p 51
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
MT and AG wrote the manuscript; CG, JPA, CT performed the experimental work; CB designed the CFTR exon phasing tool and participated in the drawing of the figures. MdG and MC supervised the study and revised the manuscript. All authors read and approved the final manuscript.
###end p 51
###begin title 52
Pre-publication history
###end title 52
###begin p 53
The pre-publication history for this paper can be accessed here:
###end p 53
###begin p 54

###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
We are grateful to VLM (Vaincre la Mucoviscidose, France) for continuous support in the study (fellowship of M.T.). We also thank the reviewers for constructive suggestions that improved the article.
###end p 56
###begin article-title 57
Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis
###end article-title 57
###begin article-title 58
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens
###end article-title 58
###begin article-title 59
Molecular pathology of the CFTR locus in male infertility
###end article-title 59
###begin article-title 60
Cystic Fibrosis Mutation Database
###end article-title 60
###begin article-title 61
Genotype and phenotype in cystic fibrosis
###end article-title 61
###begin article-title 62
Genotype-phenotype relationships in cystic fibrosis
###end article-title 62
###begin article-title 63
Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens
###end article-title 63
###begin article-title 64
Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France
###end article-title 64
###begin article-title 65
###xml 80 83 <span type="species:ncbi:9606">men</span>
Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia
###end article-title 65
###begin article-title 66
Uniparental inheritance of microsatellite alleles of the cystic fibrosis gene (CFTR): identification of a 50 kilobase deletion
###end article-title 66
###begin article-title 67
Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe
###end article-title 67
###begin article-title 68
Prenatal detection by real-time quantitative PCR and characterization of a new CFTR deletion, 3600+15kbdel5.3kb (or CFTRdele19)
###end article-title 68
###begin article-title 69
40 kilobase deletion (CF 40 kb del 4-10) removes exons 4 to 10 of the Cystic Fibrosis Transmembrane Conductance Regulator gene
###end article-title 69
###begin article-title 70
A large deletion mutation in the CFTR gene (3120+1Kbdel8.6Kb): a founder mutation in the Palestinian Arabs. Mutation in brief no. 231. Online
###end article-title 70
###begin article-title 71
Identification and characterization of three large deletions and a deletion/polymorphism in the CFTR gene
###end article-title 71
###begin article-title 72
Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms
###end article-title 72
###begin article-title 73
Rapid detection of CFTR gene rearrangements impacts on genetic counselling in cystic fibrosis
###end article-title 73
###begin article-title 74
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Frequency of large CFTR gene rearrangements in Italian CF patients
###end article-title 74
###begin article-title 75
Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening
###end article-title 75
###begin article-title 76
A large deletion in the CFTR gene in CBAVD
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Genome Variation Society web page
###end article-title 77
###begin article-title 78
Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis
###end article-title 78
###begin article-title 79
Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene
###end article-title 79
###begin article-title 80
###xml 43 48 <span type="species:ncbi:9606">Human</span>
UCSC (University of California Santa Cruz) Human Genome databases
###end article-title 80
###begin article-title 81
Universal Mutation Database
###end article-title 81
###begin article-title 82
UMD (Universal Mutation Database): 2005 update
###end article-title 82
###begin article-title 83
Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms
###end article-title 83
###begin article-title 84
Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes
###end article-title 84

